SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,645,507 | +77.4% | 388,809 | +155.8% | 0.13% | +91.4% |
Q2 2023 | $3,181,465 | +833.0% | 152,005 | +891.9% | 0.07% | +438.5% |
Q4 2020 | $341,000 | +321.0% | 15,324 | +53.2% | 0.01% | +62.5% |
Q3 2018 | $81,000 | -63.0% | 10,000 | -36.3% | 0.01% | -82.6% |
Q2 2017 | $219,000 | – | 15,689 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |